Can change in FRAX score be used to "treat to target"? A population-based cohort study

Journal of Bone and Mineral Research

Volumn 29, Issue 5, 2014, Pages 1074-1080

  Leslie, William D ^a   Majumdar, Sumit R ^b   Lix, Lisa M ^a   Morin, Suzanne N ^c   Johansson, Helena ^d   Odén, Anders ^d   McCloskey, Eugene V ^d   Kanis, John A ^d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d Centre for Metabolic Bone Disease   (United Kingdom)

Author keywords

fracture risk assessment; general population studies; menopause; osteoporosis; therapeutics

Indexed keywords

GLUCOCORTICOID;

ADULT; AGED; ARTICLE; BONE DENSITY; COHORT ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OSTEOPOROSIS; POPULATION RESEARCH; RISK ASSESSMENT; RISK FACTOR; STEROID THERAPY; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; EPIDEMIOLOGY; FOLLOW UP; HIP FRACTURES; INCIDENCE; OSTEOPOROSIS, POSTMENOPAUSAL;

AGED; FEMALE; FOLLOW-UP STUDIES; HIP FRACTURES; HUMANS; INCIDENCE; MANITOBA; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT;

EID: 84899115699     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2151     Document Type: Article

References (21)

1. Kanis JA, Oden A, Johansson H, et al. FRAX and its applications to clinical practice. Bone. 2009; 44: 734-43.
2. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2013. Available from: www.nof.org/hcp/resources/913. Accessed November 6, 2013.
3. Papaioannou A, Leslie WD, Morin S,. for the Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2010; 182: 1864-73.
4. Cummings SR, Cosman F, Eastell R, et al. Goal directed treatment of osteoporosis. J Bone Miner Res. 2013; 28: 433-8.
5. McCloskey E, Leslie WD,. Goal directed therapy in osteoporosis. J Bone Miner Res. 2013; 28: 439-41.
6. Diez-Perez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis. Osteoporos Int. 2012; 23: 2769-74.
7. Khosla S,. Surrogates for fracture endpoints in clinical trials. J Bone Miner Res. 2003; 18: 1146-9.
8. Leslie WD, Morin SN, Lix LM,. Rate of bone density change does not enhance fracture prediction in routine clinical practice. J Clin Endocrinol Metab. 2012; 97: 1211-8.
9. Fleming TR, DeMets DL,. Surrogate endpoints in clinical trials: are we being misled ? Ann Intern Med. 1996; 125: 605-13.
10. Bucher HC, Guyatt GH, Cook DJ, et al. How to use an article measuring the effect of an intervention on surrogate endpoints. JAMA. 1999; 282: 771-8.
11. McAlister FA, van Diepen S, Padwal RS, Johnson JA, Majumdar SR,. How evidence-based are the recommendations in evidence-based guidelines ? PLoS Med. 2007; 4: 250-7.
12. Leslie WD, Majumdar SR, Lix LM, et al. High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int. 2012; 23: 391-7.
13. Majumdar SR, Ezekowitz JA, Lix LM, Leslie WD,. Heart failure is a clinically and densitometrically independent risk factor for osteoporotic fractures: population-based cohort study of 45,509 subjects. J Clin Endocrinol Metab. 2012; 97: 1179-86.
14. Leslie WD, Caetano PA, MacWilliam LR, Finlayson GS,. Construction and validation of a population-based bone densitometry database. J Clin Densitom. 2005; 8: 25-30.
15. Leslie WD, Lix LM, Tsang JF,. Single-site vs multi-site bone density measurement for fracture prediction. Arch Intern Med. 2007; 167: 1641-7.
16. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA,. Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res. 2010; 25: 2350-8.
17. Fraser LA, Langsetmo L, Berger C, et al. Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int. 2011; 22: 829-37.
18. Leslie WD, Lix LM, Johansson H, et al. Does osteoporosis therapy invalidate FRAX for fracture prediction ? J Bone Miner Res. 2012; 27: 1243-51.
19. Austin M, Yang YC, Vittinghoff E, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2013; 27: 687-93.
20. Silverman SL, Cummings SR, Watts NB,. for the Consensus Panel of the ASBMR, ISCD, and NOF. Recommendations for the clinical evaluation of agents for treatment of osteoporosis. J Bone Miner Res. 2008; 23: 159-65.
21. Civitelli R, Armamento-Villareal R, Napoli N,. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int. 2009; 20: 843-51.